Board summary
Key figures
72,232
Registered population
60.6% aged 18–64
19.2%
Aged 65+
ICB 19.0% · England 17.9%
4.2%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
37.2%
In IMD quintile 1
ICB 31.9% · England 21.0%
~21,589
Core20 residents (est.)
Resident basis; registered basis ~28,357 · see page 3
12,010
Hypertension register
+7.63% in 3 yrs · England +5.60%
728
SMI register
19.3% of Cheshire West and Chester (LAD)'s
1,717
COPD register
Reviews +1.39% in 3 yrs
Forecast to 2030
14,360
Hypertension patients, 2030
+2,350 on today
74.2%
QRISK ≥20% on statins, 2030
+2.49pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews sit well below England.
Annual asthma reviews reach 49.3% (-16.4 percentage points versus England's 65.7%), leaving about 2,500 of 4,952 registered patients unreviewed.
Hypertension treatment to target lags all benchmarks.
Hypertension control is 66.6% against 70.3% in England, trailing both under-80 (64.9% vs 67.8%) and 80+ (76.6% vs 81.2%) thresholds.
Lipid-lowering therapy exceeds local and national rates.
Lipid-lowering therapy covers 69.0% of patients with QRISK ≥ 20% (England 63.6%) and 75.5% of CKD patients (England 70.3%).
Population, age and ethnicity
Older adults comprise 19.2% of registered patients alongside 20.2% aged 0 to 17
Across six practices, ONE ELLESMERE PORT PCN registers 72,232 patients. Those aged 65+ account for 19.2% (13,876 patients), below Cheshire West and Chester (20.3%), but above NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Children aged 0–17 represent 20.2% (14,594 patients), exceeding Cheshire West and Chester (18.5%), NHS Cheshire and Merseyside ICB (19.2%) and England (19.6%). Ethnicity data reflects Census usual residents, not GP registrations: 95.8% are White (Cheshire West and Chester 95.3%, NHS Cheshire and Merseyside ICB 93.0%, England 81.1%), with a 4.2% ethnic minority share.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 5.2, yet Core20 share spans 60.0 pp across practices
The PCN Core20 registered share is 37.2%, exceeding Cheshire West and Chester (15.7%), the ICB (31.9%), and England (21.0%), with an average IMD decile of 5.2. The range across captured practices is 60.0 pp. Great Sutton Medical Centre has a Core20 share of 23.4%, while Westminster Surgery reaches 83.3%. Old Hall Surgery records 69.1%, and York Road Group Practice records 62.1% with the highest volume at 7,474 estimated patients. Denominators must be reconciled, as practice estimates sum to 28,357 registered patients compared with 21,589 resident Core20 people.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
728
SMI register
1.01% recorded prevalence
506
Learning disability register
0.70% recorded prevalence
20
Care homes, 731 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
The PCN records 728 patients on its severe mental illness register (1.0%, matching England) and 506 with learning disabilities (0.7%, above England's 0.6%), alongside 20 care homes with 731 catchment beds. Annual physical checks trail England for blood pressure (78.1% vs 83.4%) and BMI (78.4% vs 82.1%). Physical check rates trailing national benchmarks could reflect recall or scheduling barriers to examine locally.
Severe mental illness: physical health checks
On the 728-patient severe mental illness register, annual blood pressure checks (78.1% vs England 83.4%) and BMI recording (78.4% vs England 82.1%) both trail national rates. Coordinated outreach is required to close physical health monitoring gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,010
Hypertension register
+7.63%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
+5.83pp
BP control, under 80
≤140/90 · +0.85pp aged 80+
+2,350
More patients by 2030
Forecast 14,360 (19.25%)
Hypertension case-finding and control
Hypertension prevalence is 16.6% (12,010 patients), above England (15.2%) but below Cheshire West and Chester (17.0%) and the ICB (16.8%), spanning from 11.4% at Westminster Surgery to 19.6% at Whitby Health Partnership. Crude unadjusted register gap scenarios range from -1,009 to +246 patients. Treatment to target reaches 66.6% against 70.3% in England and 68.9% in the borough, with under-80 control at 64.9% (England 67.8%) and aged 80+ control at 76.6% (England 81.2%). Recent blood pressure readings reach 88.4% (England 90.0%). Blood pressure control is below England across both age cohorts, so prioritising systematic blood pressure recall and titration review is an immediate operational opportunity.
Lipids and statins
Lipid-lowering therapy reaches 69.0% for patients with QRISK ≥ 20% (England 63.6%, borough 63.8%) and 75.5% for CKD (England 70.3%). Statin treatment for diabetes with prior cardiovascular disease is 86.3% (England 84.4%). Higher therapy rates than England across primary and secondary prevention cohorts indicate an opportunity to sustain strong treatment coverage for high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 139,946 | £1.40 | £1.71 | £1.86 | £195,924 |
| Cardiovascular (all), 2025 | 192,905 | £4.89 | £4.37 | £3.33 | £943,305 |
In 2026, 139,946 lipid-regulating items were prescribed at £1.40 per item (£195,924 spend), below England (£1.86), Cheshire West and Chester (£1.44) and the ICB (£1.71), spending £64,375 less than at England's unit cost. Lower unit cost than regional and national benchmarks keeps item expenditure down, so sustaining this position while maintaining clinical appropriateness is the key priority.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.01%
Asthma prevalence, PCN 3-yr % change
Recorded asthma prevalence is 7.3% (4,952 patients) against 6.6% in England, with youth prescribing at 2,466 items per 1,000 aged 5-19 versus 1,488 in England. However, annual asthma reviews fell 2.2% over three years (England +4.4%) to 49.3% (England 65.7%), leaving about 2,500 patients unreviewed. COPD reviews similarly lag at 67.0% against England's 76.4%, despite 2.4% prevalence (England 1.9%). Slower review completion alongside high prescribing may reflect recall capacity constraints to examine locally.
Cancer register and children's immunisation
The cancer register has 3,106 patients (4.3% prevalence vs England 3.8%), but three-year growth of +4.1% trailed England (+9.0%). In childhood immunisations, MMR dose 1 coverage reaches 97.1% at age 5, yet dose 2 falls 10.3 pp to 86.8%, with the gap widening to 22.8 pp at Old Hall Surgery. This drop-off indicates second-dose follow-up is an operational priority to protect coverage prior to school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Known-stage share was 72.8% (13,490 of 18,522 registered cancers). Reaching 75.0% would require about 2,640 additional early-stage diagnoses annually across the ICB, where early staging rose +2.6 pp between 2013 and 2022. Locally, PCN cancer register growth was +4.1% over 2023 to 2025, trailing England (+9.0%) and the ICB (+9.3%), which could reflect under-coding or slower recording that local clinical audit could test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Countess of Chester Hospital NHS Foundation Trust achieved 87.4% on the 28-day faster diagnosis standard, exceeding the 75.0% target and ahead of North Cheshire and Mersey NHS Foundation Trust (80.2%), Liverpool University Hospitals NHS Foundation Trust (75.5%), the ICB (77.2%) and England (79.3%). On the 62-day standard, Countess of Chester reached 83.3% (standard 85.0%), above the ICB (76.2%) and England (71.2%). Diagnostic 6+ week waits stood at 11.3% for MRI and 4.2% for CT, below England (21.4% and 9.9%), representing provider activity rather than PCN-specific performance.
| Pathways within standard (%) | Countess of Chester | Liverpool | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.37 | 75.47 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 93.48 | 90.51 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.28 | 73.26 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Countess of Chester | Liverpool | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 11.26 | 6.42 | 0.53 | 21.40 |
| CT | 4.18 | 0.71 | 2.32 | 9.92 |
| Echocardiography | 31.44 | 12.55 | 28.04 | 28.48 |
| Colonoscopy | 26.44 | 33.14 | 15.98 | 30.83 |
| Gastroscopy | 27.52 | 44.99 | 20.24 | 29.02 |
| All 15 DM01 tests | 20.16 | 11.50 | 6.34 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In June 2026, adults aged 65 and over accounted for 52.7% of all community service contacts among Cheshire West and Chester residents (25,095 of 47,655 contacts). This highlights significant borough-wide community workload concentrated in older adults, though these figures represent local authority resident activity rather than PCN-level delivery.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Hope Farm | 111 | 25.1 | 65.1% | 76.9% | 88.1% |
| York Road | 111 | 62.1 | 58.2% | 74.7% | 85.3% |
| Old Hall Surgery | 108 | 69.1 | 58.7% | 66.7% | 79.0% |
| Great Sutton | 114 | 23.4 | 43.2% | 74.4% | 76.1% |
| Whitby Health | 108 | 33.5 | 52.3% | 60.7% | 67.2% |
| Westminster | 113 | 83.3 | 62.8% | 77.9% | 67.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trail England over three years, led by asthma reviews
Across 25 tracked measures, 12 trail England's three-year change. The widest relative lags are asthma reviews (-2.2% vs England +4.4%), cancer register growth (+4.1% vs +9.0%), and stroke register prevalence (-1.7% vs +2.3%). Conversely, three-year strengths include heart failure reviews (+20.3% vs England +8.7%), blood pressure control under age 80 (+9.9% vs +3.2%), and breast screening coverage (+13.0% vs +8.4%). Slower register growth could reflect under-coding or detection differences rather than lower underlying incidence, which requires local clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Cancer register
Stroke register
Asthma register
QRISK statin treatment
Heart failure reviews
BP control, under 80
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 20 (731 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 3 | 15 | Places of worship | 23 | 231 |
| Libraries | 3 | 16 | Food banks (VCS) | 1 | 1 |
| Homelessness support (VCS) | 1 | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 12 | 70 |
| Primary academies | 9 | 46 | Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma reviews in the last 12 months reach 49.3% on the 4,952-patient register (7.3% QOF prevalence, denominator incl. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension titration and case-finding review
Hypertension treatment to target is 66.6% (England 70.3%, borough 68.9%; under-80s 64.9% vs 67.8%; 80+ 76.6% vs 81.2%), with a crude register gap range of -1,009 to +246 patients. For discussion: practices could run pharmacist-led recall and medication titration clinics alongside opportunistic blood pressure checks. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined SMI physical health checks
On the 728-patient SMI register (1.0% prevalence), annual blood pressure checks reach 78.1% (England 83.4%, borough 81.0%, ICB 81.3%) and BMI checks reach 78.4% (England 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register and screening audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension titration and case-finding review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
